Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Mustang Bio Inc. MBIO

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:MBIO)

Fundamentals Snapshot (NDAQ:MBIO)

Current News (NDAQ:MBIO)

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire 4 days ago

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

GlobeNewswire July 27, 2022

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

GlobeNewswire June 22, 2022

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

GlobeNewswire June 13, 2022

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

GlobeNewswire May 19, 2022

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire May 12, 2022

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

GlobeNewswire May 12, 2022

Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

GlobeNewswire May 3, 2022

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

GlobeNewswire April 25, 2022

Opinion & Analysis (NDAQ:MBIO)

No current opinion is available.

Bullboard Posts (NDAQ:MBIO)

it was a sell for me

this morning at $4.15 per share,it was time to take my losses on this one,used the shareholders dialogue to buy it earler this year,that...
coolfooldumbguy - August 26, 2019

it's a buy today for me

at $6.15 per share,so glta.
coolfooldumbguy - April 23, 2019

watching this one for

an entry point but waiting to see where the share price settles,so glta.
coolfooldumbguy - April 18, 2019